Palatin: FDA grants orphan drug designation to PL7737

Palatin (PTN) Technologies announced the U.S. FDA has granted “orphan drug” designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor deficiency, including obesity caused by this condition. IND submission is planned for 4Q25; Clinical data expected in 1H26.